Preemptive use of plerixafor in difficult-to-mobilize patients: An emerging concept

Transfusion

Volumn 52, Issue 4, 2012, Pages 906-914

  Jantunen, Esa ^a,b   Lemoli, Roberto M ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; PLACEBO; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ALGORITHM; APHERESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; DRUG SAFETY; HUMAN; IN VIVO STUDY; LONG TERM CARE; LYMPHOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PATIENT SELECTION; PREFERRED SOURCE OF STEM CELL; REVIEW; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ANTIGENS, CD34; CELL COUNT; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LEUKOCYTE COUNT; RECEPTORS, CXCR4;

EID: 84859772530     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03349.x     Document Type: Review

References (47)

1. Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Apperley J, Frauendorfer K, Niederwieser D,. The EBMT activity survey 2008: impact of team size, team density and new trends. Bone Marrow Transplant 2011; 46: 174-91.
2. Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, Sutherland DR, Chin-Yee IH,. Number of viable CD34(+) cells reinfused predict engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 967-72.
3. Bensinger W, DiPersio JF, McCarty JM,. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009; 43: 181-95.
4. Gertz MA,. Current status of stem cell mobilization. Br J Haematol 2010; 150: 647-62.
5. Bender JG, To LB, Williams S, Schwartzberg LS,. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329-41.
6. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B,. Peripheral blood stem cell transplantation for multiple myeloma: identification of favourable variables for engraftment in 225 patients. Blood 1995; 85: 588-96.
7. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C,. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-77.
8. Blystad AK, Delabie J, Kvaloy S, Holte H, Vålerhaugen H, Ikonomou I, Kvalheim G,. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol 2004; 125: 605-12.
9. Shpall EJ, Champlin R, Glaspy JA,. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84-92.
10. Toor AA, Ayers J, Strupeck J, Parthasanathy M, Creech S, Rodriquez T, Stiff PJ,. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. Br J Haematol 2004; 124: 769-76.
11. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF,. Impact of mobilization and remobilizaton strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-56.
12. Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U,. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009; 84: 335-7.
13. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, Goldschmidt H, Ho AD,. Poor mobilization of hematopoietic stem cells-definitions, incidence, riskfactors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490-9.
14. Jantunen E, Kvalheim G,. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies. Eur J Haematol 2010; 85: 463-71.
15. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, Hangoc G, Bridger GJ, Henson GW, Calandra G, Dale DC,. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728-30.
16. Flomenberg N, Devine SM, DiPersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G,. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-74.
17. Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman S, Litzow MR, Gastineau DA, Gertz MA,. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006; 6: 384-8.
18. Jantunen E, Putkonen M, Nousiainen T, Pelliniemi TT, Mahlamäki E, Remes K,. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilization in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347-51.
19. Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, Munshi N, Singhal S, Mehta J, Tindle S, Nelson J, Bracy D, Mattox S, Tricot G,. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16: 1547-53.
20. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, O'Coonnor C, Berkman E, Erban JK, Sprague KA, Miller KB, Schenkein DP,. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059-64.
21. Steinberg M, Silva M,. Plerixafor: a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. Clin Ther 2010; 32: 821-43.
22. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K, Grove B, Dye A, Bridger G,. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331-8.
23. DiPersio JF, Stadtmayer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwitz M, Cooper D, Bridger G, Calandra G, for the 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-6.
24. DiPersio JF, Micallef I, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G,. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-73.
25. Duarte RF, Shaw BE, Marin P, Kottaridis P, Ortiz M, Morante C, Delgado J, Gayoso J, Goterriz R, Martinez-Chamorro C, Mateos-Mazon JJ, Ramirez C, de la Rubia J, Achtereekte H, Gandhi PJ, Douglas KW, Russell NH,. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011; 46: 52-8.
26. Apperley J, Cook G, Pagliuca A, Stringaris K, Douglas K, Pozo A, Wilson K, Davies J,. Efficacy of plerixafor plus G-CSF for stem cell mobilization in patients with multiple myeloma or lymphoma who have failed prior mobilization-named patient program evaluation. Haematologica 2010; 95 Suppl. 2: 212 [abstract 0519].
27. Maziarz RT, Micallef IN, Stiff P, Bolwell BJ, Marulkar S, Calandra G, DiPersio JF,. Plerixafor plus G-CSF is an effective regimen to mobilize hematopoietic stem cells in NHL patients with circulating peripheral blood CD34+ cells/Âμl <10. Blood 2009; 114: 19 [abstract 33].
28. Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E,. Prediction of mobilization failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907-12.
29. Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F, Dingli D, Dispenzieri A, Gertz M, Greiner C, Hayman S, Inwards S, Johnston P, Lacy M, Litzow M, Porrata L, Winters JL, Kumar S,. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cut-off points for early intervention. Bone Marrow Transplant 2011; 46: 943-9.
30. Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra C,. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010; 45: 39-47.
31. Jantunen E, Penttilä K, Pyörälä M, Mahlamäki E, Nousiainen T,. Addition of plerixafor to a chemotherapy and G-CSF mobilization in hard-to-mobilize patients. Bone Marrow Transplant 2011; 46: 308-9.
32. d'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S, Dan E, Taioli S, Giudice V, Agis H, Kopecky G, Soutar R, Casadei B, Baccarani M, Lemoli RM,. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356-63.
33. Segel E, Sorensen B, d'Amore F, Hokland P,. Successful peripheral blood stem cell harvest in mobilization-refractory lymphoma patients. Bone Marrow Transplant 2010; 45 Suppl. 2: S258 [abstract].
34. Josefsen D, Rechnitzer C, Parto K, Kvalheim G,. The use of plerixafor for blood stem mobilization reduces the frequency of mobilization failure in patients planned to undergo autologous stem cell transplantation. Eur Haematol 2010; 4: 24-9.
35. Hubel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kröger N,. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2011; 46: 1053-6.
36. Basak GW, Knopinska-Posluszny W, Matuszak M, Kisiel E, Hawrylecka D, Szmigielska-Kaplon A, Urbaniak-Kujda D, Dybko J, Zielinska P, Dabrowska-Iwanicka A, Werkus J, Rzepecki P, Wroblewska W, Wiktor-Jedrzejzak W,. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor plerixafor (AMD3100)-Polish compassionate use experience. Ann Hematol 2011; 90: 557-68.
37. DiPersio JF, Ho AD, Hanrahan J, Hsu FJ, Fruehauf S,. Relevance and clinical implication of tumour cell mobilization in the autologous transplant setting. Biol Blood Marrow Transplant 2011; 17: 943-55.
38. Tricot G, Cottler-Fox M, Calandra G,. Safety and efficacy of assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumour cell mobilization. Bone Marrow Transplant 2010; 45: 63-8.
39. Fruehauf S, Ehninger G, Hubel K, Topaly J, Goldschmidt H, Ho AD, Muller S, Moos M, Badel K, Calandra G,. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumour cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2010; 45: 269-75.
40. DiPersio JF, Bridger G, Calandra G,. Effect of plerixafor (AMD3100) plus G-CSF on tumor cell mobilization among patients with lymphoma. Biol Blood Marrow Transplant 2009; 15: 37 [abstract].
41. Fruehauf S, Veldvijk MR, Seeger T, Schubert M, Laufs S, Topaly J, Wuchter P, Dillman F, Eckstein V, Wenz F, Goldschmidt H, Ho AD, Calandra G,. A combination of granulocyte colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 2009; 11: 992-1001.
42. Fruehauf S, Tricot G,. Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplant outcomes. Biol Blood Marrow Transplant 2010; 16: 1629-48.
43. Jantunen E, Fruehauf S,. Importance of blood graft characteristics in autologous stem cell transplantation: implications for optimizing mobilization regimens. Bone Marrow Transplant 2011; 46: 627-35.
44. Donahue RE, Jin P, Bonifacino AC, Metzger ME, Ren J, Wang E, Stroncek DF,. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood 2009; 114: 2530-41.
45. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK,. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 64-9.
46. Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C, Stuart RK,. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 523-8 e-pub.
47. Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K, Silva M, Steinberg M, Matous J, Selvey S, Maris M, McSweeney PA,. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophophamide. Biol Blood Marrow Transplant 2011; 17: 729-36.